This user has not added any information to their profile yet.
Barricade Therapeutics is a privately held company based in Houston, TX. We are developing TASIN and THIO, two novel, targeted small molecules, in multiple Oncology indications. Currently in preclinical stage. We are in process of completing the Families and Friends round (deadline: June 30), and are now beginning planning the next rounds (Q4 2018, followed by Q4 2019)
TASIN is a unique, first-in-class compound with a mechanism of action targeting truncated APC (adenomatous polyposis coli), one of the earliest and most critical mutations occurring in colorectal cancer (CRC). Truncated APC has a dominant role in CRC initiation and cancer progression and is expressed in 80% of those CRC tumors. Extensive preclinical work on TASIN demonstrates highly potent and selective targeting of truncated APC, resulting in significant inhibition of CRC tumor growth with no apparent toxicity to normal cells, which will make it easily combinable with existing therapies. Given APCtrunc is an early occurrence in CRC that persists throughout the treatment continuum, TASIN will become the backbone of therapy in CRC. Other disease states where APCtrunc plays an important role and TASIN will be developed are Gastric Cancer, Hepatocellular Carcinoma, Prostate, Melanoma, Uterine, NSCLC, Breast, Bladder, Pancreas, GBM, Head and Neck, and Ovarian Cancer.
THIO specifically targets tumor cell DNA and causes damage to DNA ends (telomeres), resulting in the selective death of tumor cells. This approach targets an almost universal driver of tumor growth and is supported by extensive preclinical work showing very significant antitumor activity across a broad range of tumors refractory to I/O-, BRAF-, EGFR-targeted therapies, as well as chemotherapy. Currently, patients failing these treatments have a poor prognosis and few alternative treatment options. THIO utilizes a novel mechanism of action, which successfully circumvents those resistance mechanisms, without relevant toxicity. Development of THIO will be in SCLC, NSCLC, Melanoma, Bladder, Prostate, Brain, Head and Neck, Bone, and CRC.